Closing Bell Recap: Dyne Therapeutics Inc (DYN) Ends at 14.55, Reflecting a 2.97 Upturn

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

Dyne Therapeutics Inc (NASDAQ: DYN) closed the day trading at $14.55 up 2.97% from the previous closing price of $14.13. In other words, the price has increased by $2.97 from its previous closing price. On the day, 2.4 million shares were traded. DYN stock price reached its highest trading level at $14.73 during the session, while it also had its lowest trading level at $13.99.

Ratios:

For a better understanding of DYN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.02 and its Current Ratio is at 17.02. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $46.

On November 26, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $45.

JP Morgan Downgraded its Overweight to Neutral on October 24, 2024, whereas the target price for the stock was revised from $43 to $35.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’24 when Beskrovnaya Oxana sold 2,334 shares for $28.12 per share. The transaction valued at 65,632 led to the insider holds 201,685 shares of the business.

Scalzo Richard William sold 1,455 shares of DYN for $40,915 on Dec 11 ’24. The SVP, Head of Finance & Admin. now owns 127,078 shares after completing the transaction at $28.12 per share. On Dec 11 ’24, another insider, HIGH SUSANNA GATTI, who serves as the Officer of the company, bought 5,270 shares for $28.33 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 1480695296 and an Enterprise Value of 781878720.

Stock Price History:

Over the past 52 weeks, DYN has reached a high of $47.45, while it has fallen to a 52-week low of $14.03. The 50-Day Moving Average of the stock is -43.25%, while the 200-Day Moving Average is calculated to be -54.62%.

Shares Statistics:

Over the past 3-months, DYN traded about 1.25M shares per day on average, while over the past 10 days, DYN traded about 2707850 shares per day. A total of 101.75M shares are outstanding, with a floating share count of 77.75M. Insiders hold about 23.60% of the company’s shares, while institutions hold 86.89% stake in the company. Shares short for DYN as of 1735603200 were 10515884 with a Short Ratio of 8.41, compared to 1732838400 on 10352296. Therefore, it implies a Short% of Shares Outstanding of 10515884 and a Short% of Float of 12.2700006.

Earnings Estimates

The market rating for Dyne Therapeutics Inc (DYN) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.86, with high estimates of -$0.67 and low estimates of -$1.04.

Analysts are recommending an EPS of between -$2.75 and -$3.29 for the fiscal current year, implying an average EPS of -$3.02. EPS for the following year is -$3.6, with 9.0 analysts recommending between -$2.73 and -$4.62.

Most Popular